AI assistant
Sending…
Oramed Pharmaceuticals Inc. — Director's Dealing 2021
Feb 8, 2021
6965_dirs_2021-02-08_75eec775-1730-4067-9fba-fcda5fb1669b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2021-02-03
Reporting Person: Hexter Joshua (COO, Business Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-03 | Stock Option (right to buy) | $10.40 | A | 50000 | Acquired | 2031-02-03 | Common Stock (50000) | Direct |
Footnotes
F1: The Stock Option will vest in 4 equal installments as follows: 12,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.
More from Oramed Pharmaceuticals Inc.
Interim / Quarterly Report
2026
May 19
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Director's Dealing
2026
Mar 18
Capital/Financing Update
2026
Feb 20
Major Shareholding Notification
2026
Feb 9
Director's Dealing
2026
Jan 29
Major Shareholding Notification
2026
Jan 29
Director's Dealing
2026
Jan 29